The Experts below are selected from a list of 23985 Experts worldwide ranked by ideXlab platform

Harikrishna Tandri - One of the best experts on this subject based on the ideXlab platform.

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

Neeraj Badjatia - One of the best experts on this subject based on the ideXlab platform.

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

Sihli Che - One of the best experts on this subject based on the ideXlab platform.

  • thermoelectric water Cooling Device applied to electronic equipment
    International Communications in Heat and Mass Transfer, 2010
    Co-Authors: Hsiangsheng Huang, Yingche Weng, Yuwei Chang, Sihli Che
    Abstract:

    Abstract This article investigates the thermal performance of a thermoelectric water-Cooling Device for electronic equipment. The influences of heat load and the thermoelectric cooler's current on the Cooling performance of the thermoelectric Device are experimentally and theoretically determined. This study develops a novel analytical model of thermal analogy network to predict the thermal capability of the thermoelectric Device. The model's prediction agrees well with the experimental data. The experimental result shows that when heat load increases from 20 W to 100 W, the lowest overall thermal indicator increases from − 0.75 KW − 1 to 0.62 KW − 1 at the optimal electric current of 7 A. Besides, this study verifies that the thermal performance of the conventional water-Cooling Device can be effectively enhanced by integrating it with the thermoelectric cooler when the heat load is below 57 W.

Casey Hannan - One of the best experts on this subject based on the ideXlab platform.

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

Rushil Shah - One of the best experts on this subject based on the ideXlab platform.

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P  

  • Safety and Feasibility of a Novel Transnasal Cooling Device to Induce Normothermia in Febrile Cerebrovascular Patients
    Neurocritical Care, 2020
    Co-Authors: Neeraj Badjatia, Nidhi Gupta, Stephanie Sanchez, Joseph Haymore, Hemantkumar Tripathi, Rushil Shah, Casey Hannan, Harikrishna Tandri
    Abstract:

    Background Inducing normothermia with surface Cooling temperature modulating Devices (TMDs) is cumbersome and often associated with significant shivering. We tested the safety and feasibility of a novel transnasal evaporative Cooling Device to induce and maintain normothermia in febrile patients following ischemic and hemorrhagic stroke. Methods A single-center study utilizing the CoolStat® transnasal Cooling Device was used to achieve core temperature reduction in mechanically ventilated stroke patients with fever ( T  ≥ 38.3 C) refractory to acetaminophen by inducing an evaporative Cooling energy exchange in the nasal turbinates thru a high flow of dehumidified air into the nasal cavity and out through the mouth. Continuous temperature measurements were obtained from tympanic and core (esophageal or bladder) temperature monitors. Safety assessments included continuous monitoring for hypertension, tachycardia, and raised intracranial pressure (when monitored). Otolaryngology (ENT) evaluations were monitored for any Device-related nasal mucosal injury with a pre- and post-visual examination. Shivering was assessed every 30 min using the Bedside Shivering Assessment Scale (BSAS). Duration of Device use was limited to 8 h, at which time patients were transitioned to routine care for temperature management. Results Ten subjects (median age: 54 years, BMI: 32.5 kg/m^2, 60% men) were enrolled with normothermia achieved in 90% of subjects. One subject did not achieve normothermia and was later refractory to other TMDs. Median baseline temperature was 38.5 ± 0.1 C, with a reduction noted by 4 h (38.5 ± 0.1 vs 37.3 ± 0.8, P